Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806332 · ClinicalTrials.gov registry record · NA
Glaucoma Drop Aids Part 2
A NA study, sponsored by Boston Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT06806332 is a NA study that has not yet begun recruiting, run by Boston Medical Center. The registered enrollment target is 80 participants.
The verdict
NCT06806332, a NA study, has not yet begun recruiting, sponsored by Boston Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.
Interventions
- DEVICE Nanodropper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06806332
The ClinicalTrials.gov registry entry for NCT06806332 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nanodropper is the first listed.
NCT06806332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06806332 about?
NCT06806332 is a clinical study titled "Glaucoma Drop Aids Part 2". Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an en...
What is the current status of trial NCT06806332?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-07. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06806332?
The interventions under investigation include: Nanodropper (DEVICE).
Who is sponsoring clinical trial NCT06806332?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.